Raised blood pressure is probably the single most important treatable risk factor for cardiovascular disease in later life. The evidence for benefit from antihypertensive drugs in older people has accumulated with a succession of randomised controlled trials over the past 35 years, with reduced risk of stroke and myocardial infarction as well as decreased total mortality . However, despite the extensive evidence that is now available, questions remain about who to treat and on optimal blood pressure targets. Consequently practice varies widely and many clinicians are uncertain about what best to recommend for their older patients. In this context, Age and Ageing and the Journal of the American Geriatrics Society are pleased to contribute to the debate in a joint initiative, publishing two articles that describe contrasting perspectives on this issue [2, 3]. The article by Conroy and Westendorp in Age and Aging  points out the benefits of treatment of hypertension in older persons (particularly in reducing stroke rates), however these authors emphasise the need to consider adverse effects and warn about problems caused by over-aggressive blood pressure lowering in older persons. These authors review issues related to the Systolic Blood Pressure Intervention Trial (SPRINT) , Heart Outcome Prevention Evaluation (HOPE)  and Hypertension in the Very Elderly Trial (HYVET)  studies and note that the participants in these trials are not as sick with multi-morbidity, frailty and polypharmacy as are many older persons including in general practice settings. They further emphasise the need for shared decision making with patients regarding whether or how aggressively to treat. These authors advise clinicians to consider a patient’s likely longevity and estimates of the number needed to treat to inform patients in their decisions. They recommend the current European blood pressure treatment target of 150 mmHg systolic and 90 mmHg diastolic, while emphasising clinician and patient judgement in tailoring treatment decisions. In their article for the Journal of the American Geriatrics Society, Cushman and Johnson , two leading SPRINT  investigators present a discussion of the recent American College of Cardiology and American Heart Association (ACC/AHA) guidelines  for managing high-blood pressure with a special focus on managing this disorder in older persons. The article presents a detailed rationale for why the US guidelines now recommend lower targets for systolic blood pressure and diastolic blood pressure management in older persons. The article nicely incorporates their perspectives based on the revised guidelines as well as findings from their SPRINT trial. They recommend a blood pressure threshold and treatment goal of systolic 130 mmHg and diastolic 80 mmHg in older patients with a 10-year cardiovascular disease risk of 10% or more. This includes the vast majority of persons over age 65 and all over age 70. This advice is heavily influenced by the results of the recent SPRINT trial. Although these authors do express concern over the adverse effects of blood pressure lowering, their emphasis rests more on the need for clinicians to understand that the recent guidelines and results of the SPRINT study warrant a more aggressive approach to treatment goals in older persons, particularly those who have high baseline cardiovascular disease risk. So where does this leave the clinician? For some older people blood pressure lowering for prevention of vascular disease will be a high priority, with the potential for substantial gains from setting a low treatment target. However for others antihypertensive treatment will be irrelevant or even harmful. The decision whether or not to treat hypertension in older age, and ‘how low to go’ remain a matter of expert clinical judgement, tailoring recommendations for antihypertensive treatment to the individual older person’s specific characteristics and wishes. Key points Raised blood pressure is probably the single most important treatable risk factor for cardiovascular disease in later life. There is convincing trial evidence for benefit from antihypertensive drugs with reduced risk of stroke, myocardial infarction and mortality. Questions remain about who to treat and on optimal blood pressure targets. For some older people blood pressure lowering for prevention of vascular disease should be a high priority, with the potential for substantial gains from setting a low treatment target. However for others antihypertensive treatment will be irrelevant or even harmful. The decision whether or not to treat hypertension in older age, and ‘how low to go’ remain a matter of expert clinical judgement. Conflict of interest None declared. References 1 Musini VM, Tejani AM, Bassett K, Wright JM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2009; Cd000028. 2 Conroy S, Westendorp R. Hypertension treatment for older people—navigating between Scylla and Charybdis. Age Ageing 2018; 47. 0000-0000. 3 Cushman WC, Johnson KC. The 2017 U.S. Hypertension Guidelines: what is important for older patients. J Am Geriatr Soc 2018; 66. doi:10.1111/jgs.15395. 4 SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK et al. . A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103– 16. Google Scholar CrossRef Search ADS PubMed 5 Lonn EM, Bosch J, Lopez-Jaramillo P et al. . Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016; 374: 2009– 20. Google Scholar CrossRef Search ADS PubMed 6 Beckett NS, Peters R, Fletcher AE et al. . Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887– 98. Google Scholar CrossRef Search ADS PubMed 7 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Col Cardiol 2017. www.onlinejacc.org/content/early/2017/11/04/j.jacc.2017.11.006.extract.jpg17. © The Author(s) 2018. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: firstname.lastname@example.org This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)
Age and Ageing – Oxford University Press
Published: May 21, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera